{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Among the first phase of 8 patients, there is at least 57% probability of observing one or more rare (10% true probability) events, and 73% probability of observing one or more toxicities that have a true occurrence rate as low as 15%. Among the total cohort of 25 patients, there is at least 84% probability of observing one or more rare (7% true probability) events, and 93% probability of observing toxicities that have a true occurrence of at least 10%. With 25 treated patients, the maximum width of a 90% two-sided exact binomial confidence interval for any estimated adverse event proportion will be no wider than +/- 18%.","groups":[{"description":"Patients receive nivolumab IV over approximately 60 minutes followed by a saline flush and ipilimumab IV over 90 minutes. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.\n\nIpilimumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG000","title":"Cohort B (Nivolumab and Ipilimumab)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Please refer to adverse event module for detailed list of adverse events. Percentage of participants who experienced adverse events.","reportingStatus":"POSTED","timeFrame":"Up to 4 cycles","title":"Incidence of Toxicity, Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (Version 5.0 Beginning April 1, 2018) (Cohort B)","type":"SECONDARY","unitOfMeasure":"Participants"}